STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy
Preprint
Abstract
The stimulator of interferon genes (STING) pathway links innate and adaptive antitumor immunity and therefore plays an important role in cancer immune surveillance. This has prompted widespread development of STING agonists for cancer immunotherapy, but pharmacological barriers continue to limit the clinical impact of STING agonists and motivate the development of drug delivery systems to improve their efficacy and/or safety. To address these challenges, we developed SAPCon, a STING-activating polymer-drug conjugate platform based on strain-promoted azide-alkyne cycloaddition of dimeric-amidobenzimidazole (diABZI) STING agonists to hydrophilic polymer chains through an enzyme-responsive chemical linker. To synthesize a first-generation SAPCon, we designed a diABZI prodrug modified with a DBCO reactive handle with a cathepsin B-cleavable spacer for intracellular drug release and conjugated this to pendant azide groups on a 100kDa poly(dimethyla acrylamide- co -azide methacrylate) copolymer backbone to increase circulation time and enable passive tumor accumulation. We found that intravenously administered SAPCon accumulated at tumor sites, where it was endocytosed by tumor-associated myeloid cells, resulting in increased STING activation in tumor tissue. Consequently, SAPCon promoted an immunogenic tumor microenvironment, characterized by increased frequency of activated macrophages and dendritic cells and improved infiltration of CD8 + T cells, resulting in inhibition of tumor growth, prolonged survival, and enhanced response to anti-PD-1 immune checkpoint blockade in orthotopic breast cancer models. Collectively, these studies position SAPCon as a modular and programmable platform for improving the efficacy of systemically administered STING agonists for cancer immunotherapy.Keywords
All Related Versions
- Published version: ACS Central Science, 10 (9), 1765.
This publication has 50 references indexed in Scilit:
- Enhanced Humoral Immune Response by High Density TLR Agonist Presentation on Hyperbranched PolymersAdvanced Therapeutics, 2021
- Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administrationJournal of Controlled Release, 2021
- HPMA-based polymeric conjugates in anticancer therapeuticsDrug Discovery Today, 2020
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityCell Reports, 2015
- The STING pathway and the T cell-inflamed tumor microenvironmentTrends in Immunology, 2015
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic TumorsImmunity, 2014
- Polymer–drug conjugates: Origins, progress to date and future directionsAdvanced Drug Delivery Reviews, 2013
- HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activityJournal of Controlled Release, 2012
- 929 Clinical phase I trial of PK1 (HPMA co-polymer doxorubicin)European Journal of Cancer, 1995